47 Rue Adrienne Bolland
Ncardia collaborates to excel
Ncardia is supported by the European Union’s Horizon 2020 research and innovation programme through an SME Instrument grant. This grant gives Ncardia the opportunity to further develop and improve its safety pharmacology assays as well as developing novel cardiac disease models and high-throughput screening assays for cardiovascular drug discovery.
Three European technology SME’s, Luxcel Biosciences Ltd, Axiogenesis AG and BMG LABTECH GmbH, together with two internationally recognised research institutions, Oxford University and Imperial College London, have been awarded funding from the European commission under the H2020 Fast Track to Innovation (FTI) pilot, to develop and launch a cell metabolism analysis platform that is predicted to be part of routine in vitro cell biology and drug development.
In HeartCHIP, supported by the Eurostars Programme, Ncardia will leverage its unique expertise in cardiac disease modeling and work in close collaboration with the German company ibidi GmbH, a leading supplier of cell-based assays, and the Erasmus University Medical Centre Rotterdam, located in The Netherlands. The partners within the HeartCHIP consortium will combine their unique proprietary technologies to develop extensive new knowledge and co-develop a breakthrough cardiac phenotypic screening platform.
Plurimes combines the expertise of eight academic and two industrial partners to bring together stem cell experts, genetic engineers, developmental biologists, cell therapy pioneers, bioengineers and specialist SMEs in a cross-disciplinary collaborative effort. PluriMes is supported through the European Commission’s Framework 7 HEALTH research programme and Coordinated by Professor Austin Smith from the Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute at the University of Cambridge.
In the InForMed project an integrated pilot line for medical devices will be established, covering the complete innovation chain from technology concept to system qualification. It will include micro-fabrication, assembly and even the fabrication of smart catheters. Ncardia is active in the development of demonstrator products within the consortium, in particular demonstrator 2: Advanced devices for electrophysiology. InForMed is an ECSEL JU project and is co-funded by grants from Belgium, Finland, France, Germany, Great Britain, Ireland, the Netherlands, Spain, Sweden and Switzerland.
Ncardia is involved in the Comprehensive in vitro Proarrhythmie Assay (CiPA) initiative, led by the US FDA, Safety Pharmacology Society (SPS), Cardiac Safety Research Consortium (CSRC) and Health & Environmental Sciences Institute (HESI). This project aims to improve current regulatory guidances by introducing predictive technologies, including human stem cell-derived cardiomyocytes, into preclinical cardiac safety assessment. This assay, designed to assess proarrhythmic risk during new drug development, will ultimately drive the modification or replacement of the existing ICH S7A/B guidelines and elimination of E14 guidelines, virtually eliminating the need for clinical TQT studies for compounds entering clinical development.
Ncardia, in a consortium with 4 academic partners and one SME, won the CRACK IT InPulse challenge for development of a cardiac contractile assay. A panel of experts from GSK, AstraZeneca, NC3Rs and renowned academic institutions selected the consortiums solutions from a strong line-up of competing technologies. The consortium will develop an assay to detect cardiac contractility effects at an early stage of drug development.